The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

COPD-asthma-devices-market2025 PORTLAND, DE, UNITED STATES, January 29, 2025 /EINPresswire / -- Day-to-day exposure to environmental pollutio ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic ...

Conclusion: Budesonide Clickhaler® and budesonide Turbuhaler® dry powder inhalers demonstrated similar pharmacokinetic profiles, pulmonary bioavailability and systemic activity. As this was a ...

Novartis and Qualcomm are to develop a 'smart' COPD inhaler to allow patients to digitally monitor their medication. The announcement follows similar plans by Novartis's rivals in the respiratory ...

With the US capping inhaler prices at $35 ... a significant share of the moderate-to-severe COPD market segment. “With Fasenra and Breztri, AstraZeneca is well-positioned to dominate the ...

Dupixent’s success has highlighted the potential of biologics to target specific inflammatory pathways in COPD, a space previously dominated by inhaled therapies. AstraZeneca’s Fasenra ...